C linical trials investigating the effectiveness of new treatments for Alzheimer disease may report outcomes across multiple domains including outcomes relevant to the patient, the caregiver, and the health care system. [1] [2] [3] [4] [5] [6] [7] In the typical framework explaining the relationship between these outcomes, scientists might hypothesize that an intervention improves patient cognition or behavior which then leads to improved patient quality of life and reduced caregiver stress, and these improvements thereby lead to decreased health care use. [8] [9] [10] Among older adults with Alzheimer disease, reducing health care cost is an important target because older adults with dementia accrue much higher health care costs that those without dementia. [11] [12] [13] Delaying time to institutionalization has been a particularly high-value goal because this is an important outcome for patients, caregivers, and third-party payers. 8, 9, 14 Indeed, nursing home care is so expensive that treatments that might be considered otherwise too expensive can be justified if they are able to demonstrate savings in the cost of nursing facility care. 8, [15] [16] [17] Resource use surveys have been developed for use in general population studies and also for use among older adults with dementia. [18] [19] [20] These instruments query respondents and their caregivers about the frequency of episodes of care, lengths of stay for hospitalizations or nursing facility care, and may also seek to identify specific dates, for example, of institutionalization. Some of these surveys also seek to quantify the cost of unpaid caregiving. Most Alzheimer disease clinical trials that measure the use of health services rely on surveys of caregiver's self-reports of patient's use of health services. 3, 18, [21] [22] [23] The "proxy selfreports" of health care use can be converted to estimates of total health care costs by assigning an average monetary value to each episode of care, such as the average cost of a Medicare hospital stay.
Self-reports of health service use are known to have substantial error. [24] [25] [26] [27] [28] Respondent errors may be due to recall bias, telescoping (recall of events correctly but not in the correct time frame), or perceptions of social acceptability. 28 The potential bias introduced by systematic and nonsystematic error in self-reported health care use varies based on the study population, hypothesis, and design. 28 We previously conducted a randomized controlled clinical trial of collaborative care for older adults with Alzheimer disease. 29 As part of this clinical trial, we collected data on resource use from subjects' caregivers using the Resource Use Inventory. 30 We also obtained utilization data from the local electronic medical record to supplement the self-reported data in the original clinical trial. More recently, we obtained subjects' actual Medicare and Medicaid claims data as well as their standardized nursing home and home health care assessments. The specific aim of this study was to assess the accuracy of self-reports of health care use among older adults with Alzheimer disease and their caregiver proxy respondents. We then use these findings to simulate the impact of errors in self-reports on sample size and power considerations in clinical trials of Alzheimer disease seeking to demonstrate difference in health care use between experimental groups. We pursued these simulations because most Alzheimer disease clinical trials are small (< 200 subjects) and yet the consumers of these studies often demand cost-effectiveness evidence which is most often derived through data on selfreported utilization. Thus, error within these self-reports could results in study conclusions that show no effect of the intervention on utilization when one actually exists (due to inadequate statistical power). Even in the setting of adequate power, the study could report an effect of the intervention that was biased (an effect size that is erroneously too high or too low) due to errors from self-reports.
METHODS
This study was approved by the Indiana University Purdue University-Indianapolis Institutional Review Board and the Centers for Medicare and Medicaid Services Privacy Board. The current report focuses on the 100 subjects enrolled from an urban safety net health system serving the Indianapolis area and randomized to intervention or control groups. 29 Because the study intervention did not alter capacity for self-reported health care use, we report the results of these 100 subjects in aggregate. All subjects enrolled in the original trial were enrolled as dyads so that all subjects with Alzheimer disease were enrolled with an informal caregiver. The original clinical trial was powered to demonstrate clinically significant differences in the Neuropsychiatric Inventory and was not powered to demonstrate differences in health care use between experimental groups.
Data from this study come from 2 sources: (1) selfreported utilization data as reported by the caregiver and collected in the prior clinical trial; and (2) actual utilization data as documented in medical records and claims data for the same period covered by the self-reported utilization data. 11 The clinical trial used the Alzheimer's Disease Cooperative Studies Group Resource Use Inventory. 19, 30 This instrument was delivered by professional research assistants in telephone interviews at baseline (covering the 6 mo before baseline), 6, 12, and 18 months. The Resource Use Inventory includes questions about assistive devices, examinations by doctors or nurses, use of adult day care, and hours of nonprofessional caregiving. For the purposes of this project we focused on the 4 items below:
In the last 6 months, how many different visits has [subject] had to a hospital emergency room or urgent care facility In the last 6 months, how many times was [subject] admitted to the hospital? In the last 6 months, how many nights did [subject] spend in the nursing home? In the last 6 months, how many days did a home health aide, attendant or any other paid individual look after [subject]?
We focused on these 4 outcomes because they represent the high-cost health care utilization patterns of concern to third-party payers and the utilization patterns that Alzheimer disease interventions seek to decrease. Actual utilization data were documented in a unique data set in which we merged the clinical data available from a regional health information exchange 31 with 4 additional databases: (1) Medicare claims; (2) Resident Level Minimum Data Set; (3) Outcome and Assessment Information Set; and (4) Indiana Medicaid claims. Through this comprehensive database, we can document health care use across health care systems and across the continuum of care. Thus, the data on utilization are not limited to data collected at a single health care system or a single payor. Episodes of care within this database include documentation of actual dates of use so we can place use within the baseline (À 6 to 0 mo), 6 months (0 to 6 mo), 12 months (7 to 12 mo), and 18 months (13 to 18 mo) windows used in the self-report data. Alternatively, total use over the entire time period can be summed from self-report or claims data. For each patient, we determined all emergency department use, all hospitalizations, all nursing facility use, and all home health use for each of the time periods corresponding to the self-report survey. We used data available in any of the merged data sets to capture any of these episodes of care including Minimum Data Set and Outcome and Assessment Information Set data.
For each subject, we compared the self-reported data for use in any of the 4 care sites (emergency department, hospital, nursing home care, or home health care) first by looking at agreement on whether any use occurred. We report k-statistics for each 6-month period for each of the 4 sites of care using any use as the comparison unit. This requires the respondent only to correctly report if use in the site occurred in the past 6 months as a yes or no question. We also report the percentage of patients who overestimated or underestimated use. To explore respondents' accuracy on the volume of use, we examined agreement on the volume of use (number of emergency department visits, number of hospitalizations, number of nights in the nursing home, and number of days of home health care).
Using data from the prior clinical trial, we designed a simulation to demonstrate the impact of various rates of underreporting and overreporting of health care use on the estimated power for an equal-sized 2-group comparison study. In the simulation, we assumed that a generic self-reported care utilization count for the ith subject followed a negative binomial distribution with mean (ie, annual rate) of l i , and variance l i + kl i 2 , where k was the dispersion parameter indicating the level of data dispersion. Of note, power calculations on utilization counts in most clinical trials are based on a Poisson data assumption. The negative binomial distribution is a more general family of distributions that includes the Poisson distribution as a special case: when k = 0, Y i BPoisson(l i ). Under the standard formulation of log linear regression models, we expressed the subject-specific care utilization rate as l i ¼ expðb 0 þb 1 Group i þb 2 Under i þb 3 Over i ) where b 0 was the logarithmically transformed overall annual rate of utilization; Group i was the treatment indicator for the ith subject (Group i = 1 if the subject had received the intervention and Group i = 0 if the subject had received usual care), and b 1 was the average treatment effect; Under i was an indicator for utilization underreporting (Under i = 1 indicated the utilization count was underreported, and Under i = 0 if utilization was not underreported), and b 2 represented the magnitude of underreporting; similarly, Over i was an indicator for overreporting (Over i = 1 if utilization was overreported), and b 3 represented the magnitude of overreporting. In the simulation, we set b 0 = log e (1) = 0 (on average 1 utilization event per year), b 1 = log e (0.8) (ie, 20% reduction in utilization rate in intervention group), and for b 2 we considered 2 different values: b 2 = log e (0.7) and b 2 = log e (0.5) (ie, 30% and 50% reduction in those who underreported their utilization counts); for b 3 we used b 3 = À log e (0.7) (ie, 30% inflation in utilization counts in those who overreported their utilization counts). We considered scenarios where sample size per treatment arm ranged from 150 to 900 at 150 increment; for a given sample size, we assumed that 1/3 of the subjects who had reported utilization correctly, whereas 1/6, 1/3, or 1/2 of the subjects had either overreported or underreported their care utilization. Using count data generated from the negative binomial model, we compared the simulated power to the situation of no biased reporting. For each parameter setting, we generated 20,000 data sets. The simulated power corresponding to each sample size was presented graphically. Table 1 describes the clinical characteristics of the 100 subjects. In general, these subjects are similar to those in typical Alzheimer disease clinical trials as measured by age, sex, and cognitive function. However, these subjects also suffer from a significant number of comorbid conditions consistent with the original trial's goal to enroll a sample representative of patients with dementia in primary care. Table 2 shows the agreement between actual use and self-reported use when respondents are only required to correctly reported "any use" as compared with "no use." In this table, the cumulative reporting period increases by 6 months across each column. In general, across the 4 sites of care, respondents tended to underreport use. Even in the setting of rare but hypothetically notable events, such as nursing facility use, there was underreporting. Table 3 again shows the agreement between actual use and self-reported use when respondents are only required to correctly reported "any use" as compared with "no use." As compared with Table 2 , in Table 3 the reporting period is for each 6month reporting period. In both Tables 2 and 3 , k-statistics are generally poor. Table 4 shows agreement between selfreports of volume of use and actual volume of use for the first 6-month reporting period and the first and second 6-month reporting periods combined (12 mo aggregate). Notably, a large percentage of subjects have no utilization in these sites of care and levels of agreement in volume are driven largely by the number of respondents correctly reporting "zero use." Despite the high likelihood of zero use, agreement as measured by the k-statistic is poor across all 4 sites of care.
RESULTS
We then conducted a simulation study to determine the impact of underreporting and overreporting on the statistical power of a hypothetical clinical trial of a novel Alzheimer disease intervention seeking to reduce health care costs. We also describe the potential for bias in outcome findings. Herein, we generated count data where intervention subjects had a 20% reduction in utilization rate as compared with control subjects and we contend that a difference of such magnitude would constitute a clinically meaningful and economically important reduction in use. Count data in this scenario could be either hospitalizations or nursing home stays. Although many clinical trials are powered to demonstrate clinically important differences in continuous outcomes such as cognition or behavioral symptoms, we focused specifically on the power implications of amnestic underreporting on these high-cost utilization outcomes. We considered scenarios of varying proportions of subjects' underreporting and overreporting their care use as well as the magnitude of underreporting. In each figure, we report the impact of this error based on proportions of respondents in different scenarios: (1) 1/3 no bias (no errors), 1/3 underreport, 1/3 overreport; (2) 1/3 no bias, 1/2 underreport, 1/6 overreport; and (3) 1/3 no bias, 1/6 underreport, and 1/2 overreport. In Figure 1 the magnitude of underreporting is 30% and in Figure 2 it is 50% (Fig. 2 ) lower than the actual rate of care utilization. In both the figures, the magnitude of overreporting is 30%.
In the absence of self-reporting bias in both Figures 1  and 2 , the hypothetical study seeking to demonstrate a 20% reduction in counts of hospitalizations or nursing home stays at 80% power would require approximately 525 subjects per group for a total sample size of 1050. In Figure 1 , with 50% of subjects underreporting events by 30% and 1/6 overreporting the events by 30%, the required sample size to maintain a power of 80% would grow to approximately 600 subjects per group or a total sample size of 1200 subjects. In Figure 2 , with 50% of subjects underreporting events by 50% and 1/6 overreporting events by 30%, the required sample size to maintain a power of 80% would grow to approximately 675 subjects per group or a total sample size of 1350 subjects. Although not shown in the Figures, multiple other factors would also inflate the estimated sample size. For example, we assumed that the bias in self-reports was not differential between the experimental groups but we note that a differential bias in reporting would further inflate the estimated sample size. The current simulation assumed a negative binomial distribution in the count variables and did not consider the possibility of an excessive number of zero events. If the analysis considered the likely inflation of zero events in the distribution of events such as hospitalizations or nursing home stays, this would also inflate the estimated sample size.
Although the simulation above focuses on the power and sample size implications of biased patient self-reports, overreporting of care utilization also biases the estimation of treatment effect. In other words, patient overreporting of care utilization affects not only the power of the test but also the estimation of the treatment effect. Figure 1 focuses on the power consequences of overreporting and underreporting. When a significant number of the study subjects overreport their utilization, the analytical power appears to be inflated (improved). But this power inflation comes at the expense of increased bias in treatment effect estimation. Thus, bias in self-reporting translates into bias in the estimated effect size.
Except for the no bias reporting scenario, all settings with underreporting or overreporting also resulted in biased treatment effect estimates. In the scenario where 1/3 had no bias, 1/3 had underreporting and 1/3 had overreporting, the magnitude of the average bias was 4.5% of the true reporting bias, 1/6 had underreporting, and 1/2 had overreporting (which appeared to have the best power) actually had the worst level of bias in treatment effect estimate. In other words, the power inflation resulting from misreporting was achieved at the expense of substantially increased treatment effect bias. For Figure 2 , the corresponding average treatment effect bias is 3%, 18%, and 13%. wPercentage refers to the number of persons reporting no use divided by the number with some actual use; for example, reporting no ED visits when some À6 to 0 months 22/39 = 27.9%.
zk-statistic. NA indicates not applicable.
DISCUSSION
Self-reports of health care use and hours spent in caregiving have been used to estimate the total cost of care for older adult with Alzheimer disease. 5, 8, 12, 13, 32 These reports consistently demonstrate higher costs of care for these patients relative to older adults without dementia. These self-reports also demonstrate the substantial cost of informal caregiving in the home as well as the cost of professional caregiving in the home or the nursing home. In these prior studies, respondents typically report events such as hospitalizations or hours spent in caregiving over a fixed time interval such as 6 months or 1 year. These events are then translated into costs based on market estimates or other metrics relevant to the particular study and depending on the research team's decisions on assuming a societal perspective versus another economic perspective. Given the large differences in health care utilization between persons with dementia compared with those without dementia (including a large percentage of older adults with no hospitalizations or nursing home stays in a given year), this method of self-reported utilization provides valid estimates of the overall cost of dementia. However, it is less clear that self-reports of use are sufficiently accurate to allow comparisons between experimental groups of persons with Alzheimer disease. Using data from an actual Alzheimer disease clinical trial and a comprehensive database capturing health care utilization across the continuum of care, we demonstrate the magnitude of inaccuracy in self-reports. Caregivers tend to underreport use although errors in overreporting also exist. We show that this bias in self- reports can substantially reduce statistical power in randomized trials and thereby increase the risk of a type II error, and these errors can also produce treatment effect bias that could produce inaccurate conclusions about the study results. The use of self-reports rather than actual claims data is often justified through an argument that self-report data are less expensive to obtain. If the use of self-reports requires a larger sample size, however, self-report data may ultimately require a more expensive clinical trial. Most clinical trials to date have been powered based on outcomes such as cognition or behavior. 16, 17 These continuous variables, measured directly by the research team, often allow adequate statistical power at smaller sample sizes. Indeed, the typical Alzheimer disease trial identified in recent systematic reviews had a sample size of <200 subjects. 6, [33] [34] [35] In additional or secondary analyses, researchers may use selfreport data collected during these trials to ascertain whether the intervention reduced health care use or costs or delayed institutionalization. In studies enrolling <350 subjects per group, utilization counts would have to drop more than the 20% simulated in the current study to demonstrate a statistically significant difference between groups. In costeffectiveness analyses, error in self-report may be further magnified because events are translated into average costs per event. Cost data are highly skewed with large numbers of persons with zero or near-zero costs. Thus, in the setting of small sample sizes, one subject overreporting or underreporting estimated high-cost events can have a substantial impact on the study conclusions. In addition, differential bias in self-reports, particularly in the timing of events such as nursing home use, could result from respondents' perceptions of social desirability. A differential bias in selfreports could occur, for example, in a study where the intervention cannot be double-blinded such as an intervention designed to delay institutionalization through caregiver education and support.
In 1999, we reported on the limitations of using selfreport data to investigate health services use among a community-based sample of older adults. 25 That study relied on a very different population that was a stratified random sample of 422 patients aged 60 and older who had visited the urban public health care system at least once in the previous 3 months. We completed a telephone interview to obtain subjects' self-reported health care use and compared these self-reports with data that were limited to local electronic medical records. Comparing self-report data to the electronic record data, 24% of older adults with a hospitalization in the prior 12 months failed to report the episode and 28% of those with an emergency room visit failed to report the episode. Like the current study, selfreports of frequency of these services were substantially underreported. In 2006, Bhandari and Wagner published a systematic review of 42 studies reporting on the accuracy of self-reported utilization data. The authors concluded that self-report data are of "variable accuracy" and that accuracy is affected by both telescoping and memory decay. Telescoping occurs when events are remembered to have occurred but respondents place the event in the wrong time period. The authors found that telescoping occurred regardless of the recall timeframe and did not produce a consistent bias. The review also revealed that underreporting was the most frequent problem and that underreporting is made worse in the setting of increased health care use and older age. In the Bhandari and Wagner review, there were no studies that assessed the accuracy of proxy self-reports of health care use among older adults with dementia.
The term "underreporting" can be viewed from different perspectives because the data are dominated by zero values and it is not necessary clear whether underreporting 1 event in the context of 1 episode of care is more or less important than underreporting 1 event in the context of many episodes of care. We have attempted to present and analyze the data in the manner most consistent with how the data are typically handled in a clinical trial and subsequent cost-effectiveness analyses. Extant studies rarely compare mean days of use for items like hospital, nursing home, or home health care because the distribution is severely skewed and dominated by zeros and this skewness is made more problematic by the relatively low number of enrolled subjects in a typical Alzheimer disease trial. The analyses in those studies, particularly for the nursing home outcomes which has been viewed as the most salient, is either "time to first use" or "any use."
The timing of nursing facility use has become an important metric for potential cost savings because delaying institutionalization by several months could amount to important cost savings. However, the results of our study suggest that proxy self-respondents may have difficulty in identifying an episode of nursing facility care and its precise timing or dates. Part of this difficulty may come from the vagaries inherent in terms such as "nursing home" and "institutionalization." In the current environment in the United States, the same facility might provide for long-term care, subacute rehabilitation, hospice care, or respite care. We have previously documented the dynamic movement of patient with dementia from home to hospital to nursing home and back to home. 11 Over the time period of this study, subjects could also have spent time in "hospitalbased long-term care," "long-term acute care facilities," assisted living settings, and rehabilitation centers. Because the term "nursing home" connotes both permanent institutionalization and short-term rehabilitation and because similar care can be provided in any of these settings and the home, respondents could understandably be confused by these terms. It is unlikely that survey questions completed by lay respondents could keep abreast of the changing landscape of nursing facilities and their capabilities.
This study has limitations. First, these results may not generalize to nationally representative samples of older adults with dementia. This is a small sample from an urban public health care system, but the sample size is similar to the majority of prior clinical trials studying older adults with dementia. Second, although we have assembled a comprehensive database of health care use across the care continuum, we would not necessarily have identified private insurer pay or self-pay ambulatory care visits or hospitalizations. The database does capture private insurer pay or self-pay nursing facility use or home health care use. Third, the database we assembled is expensive and the cost of collecting such claims data may be greater than the cost of expanding a study's sample size.
We conclude that proxy self-reports of health care use appear to contain significant error, and the magnitude of the error is sufficient to reduce statistical power and introduce bias into treatment effect results. Gathering actual utilization data or adjudicating proxy respondent's selfreports should be encouraged for those trials where utilization is a primary outcome.
